USCWA
AKBA icon

U.S. Capital Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,871
Closed -$1.08K – 662
2022
Q4 		$1.08K Buy
+1,871
New +$586 ﹤0.01% 1530

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

U.S. Capital Wealth Advisors's AKBA Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2023, closing a stake of 1,871 shares — an estimated $1.08K sold.

U.S. Capital Wealth Advisors first reported a position in AKBA in Q4 2022 and held it in 1 quarter. The position peaked at $1.08K in Q4 2022. 65 funds tracked by Wall St. Rank hold AKBA as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Akebia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 1,871 Akebia Therapeutics shares in Q1 2023, an estimated $1.08K.
  • U.S. Capital Wealth Advisors first reported a position in Akebia Therapeutics in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Akebia Therapeutics position peaked at $1.08K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.